Why the study?
Glucocorticoids are commonly used to treat rheumatoid arthritis, but their safety profile, common adverse events, and safe dosing thresholds require ongoing evaluation.
Does glucocorticoid use increase the risk of adverse events in patients with rheumatoid arthritis?
Does glucocorticoid use increase the risk of adverse events in patients with rheumatoid arthritis?
The review highlights that while glucocorticoids are effective for rheumatoid arthritis, their use is associated with dose- and duration-dependent adverse events, necessitating individualized, minimal effective dosing.
Supports minimizing glucocorticoid dose and duration in RA; leaves open precise thresholds from prospective trials.
Glucocorticoids (GCs) are one of the most commonly used drugs for the treatment of rheumatoid arthritis (RA), the effectiveness of which is beyond doubt. The review considers current literature data on the safety of GCs use, as well as the most common adverse events associated with such therapy. Most authors point to an increased risk of complications with an increase in the daily dose and/or duration of GCs treatment. At the same time, a safe dose of GCs has not been determined. Probably, the optimal tactic is the selection of an individual dose of GCs in each individual case, taking into account the activity of RA and the spectrum of comorbid conditions. In this case, the minimum effective doses and short courses of GCs should be used, regular monitoring of clinical and laboratory parameters should be carried out in order to detect adverse events early.
No takes yet. Share an insight, caveat, or question.
Aronova et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: